UBS analyst Kevin Caliendo lowered the firm’s price target on Humana to $620 from $645 and keeps a Buy rating on the shares. Humana’s 2023 outlook appears conservative, with management baking in numerous headwinds related to investments in MA offerings, Medicaid growth/redeterminations, and a return to normal utilization levels, and the firm feels there is still some uncertainty around what the long-term impact of RADV will be on Humana, the analyst tells investors in a research note. Additionally, the advanced rate notice from CMS also raises some new questions around coding, but UBS does not think it will have a material impact on the benefit offerings and value proposition of Humana.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HUM:
- Humana appoints Sanjay Shetty to lead health care services business
- Humana sees FY23 adjusted EPS ‘at least’ $28.00, consensus $28.00
- Humana reports Q4 adjusted EPS $1.62, consensus $1.46
- Humana’s (HUM) New Defense Contract Extension Could Be Worth $16.26B
- Evolent Health price target raised to $59 from $57 at Cowen
